Glycomet belongs to a group of medicines called biguanides. Glycomet lowers high blood glucose (hyperglycaemia) by helping your body make better use of the insulin produced by your pancreas.
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Unlike sulfonylureas, Glycomet does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With Glycomet therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
Glycomet is used to control blood glucose (the amount of sugar in the blood) in people with diabetes mellitus. Glycomet can be used in: type 1 diabetes, also called insulin dependent diabetes or juvenile onset diabetes, when insulin alone is not enough to control blood glucose levels; type 2 diabetes, also called non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes. It is especially useful in those who are overweight, when diet and exercise are not enough to lower high blood glucose levels (hyperglycaemia).
<div> Glycomet can be used alone, or in combination with other medicines for treating diabetes. Glycomet is not recommended for use in children, except for those with insulin-resistant diabetes who are being treated in hospital.